Kyle Matschke

741 total citations
60 papers, 545 citations indexed

About

Kyle Matschke is a scholar working on Surgery, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Kyle Matschke has authored 60 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 12 papers in Public Health, Environmental and Occupational Health and 11 papers in Molecular Biology. Recurrent topics in Kyle Matschke's work include Pain Management and Opioid Use (10 papers), Migraine and Headache Studies (10 papers) and Diabetes Treatment and Management (10 papers). Kyle Matschke is often cited by papers focused on Pain Management and Opioid Use (10 papers), Migraine and Headache Studies (10 papers) and Diabetes Treatment and Management (10 papers). Kyle Matschke collaborates with scholars based in United States, France and United Kingdom. Kyle Matschke's co-authors include Joan Korth‐Bradley, Virginia Parks, Lawrence Fleckenstein, Haihong Shi, Daniela Soriano Pignataro, Poe‐Hirr Hsyu, Vaishali Sahasrabudhe, Steven G. Terra, Alain Patat and Anne Hickman and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, American Journal of Tropical Medicine and Hygiene and Clinical Pharmacokinetics.

In The Last Decade

Kyle Matschke

56 papers receiving 530 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyle Matschke United States	15	116	96	95	83	71	60	545
Lihua Zhang China	14	81 0.7×	117 1.2×	56 0.6×	26 0.3×	22 0.3×	63	584
Victor Dumitraşcu Romania	17	130 1.1×	56 0.6×	77 0.8×	26 0.3×	41 0.6×	48	620
Ricardo Pérez-Fuentes Mexico	16	109 0.9×	32 0.3×	108 1.1×	21 0.3×	72 1.0×	52	651
Paolo Brambilla Italy	15	176 1.5×	75 0.8×	122 1.3×	12 0.1×	18 0.3×	47	906
M Homeida Sudan	14	65 0.6×	82 0.9×	37 0.4×	77 0.9×	302 4.3×	24	693
Pinky Jha United States	12	116 1.0×	56 0.6×	79 0.8×	58 0.7×	6 0.1×	47	561
Cornelis Smit Netherlands	12	28 0.2×	126 1.3×	24 0.3×	177 2.1×	18 0.3×	22	424
Verónica Franco United States	16	98 0.8×	78 0.8×	90 0.9×	19 0.2×	7 0.1×	59	880
Waleed H. Albuali Saudi Arabia	14	77 0.7×	70 0.7×	42 0.4×	75 0.9×	5 0.1×	49	696
Daniel Malița Romania	15	74 0.6×	139 1.4×	17 0.2×	12 0.1×	36 0.5×	42	540

Countries citing papers authored by Kyle Matschke

Since Specialization

Citations

This map shows the geographic impact of Kyle Matschke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle Matschke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle Matschke more than expected).

Fields of papers citing papers by Kyle Matschke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle Matschke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle Matschke. The network helps show where Kyle Matschke may publish in the future.

Co-authorship network of co-authors of Kyle Matschke

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle Matschke. A scholar is included among the top collaborators of Kyle Matschke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle Matschke. Kyle Matschke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matschke, Kyle, et al.. (2026). The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants. Clinical Therapeutics. 48(2). 179–185. 1 indexed citations

Yang, Derek Z., et al.. (2025). Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. British Journal of Clinical Pharmacology. 91(12). 3501–3510. 1 indexed citations

Bhardwaj, Rajinder, Jennifer Madonia, Kyle Matschke, et al.. (2024). Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults. Headache The Journal of Head and Face Pain. 65(2). 315–325. 5 indexed citations

Bhardwaj, Rajinder, Julie L. Collins, Jennifer Madonia, et al.. (2024). Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel. Headache The Journal of Head and Face Pain. 65(1). 14–23. 3 indexed citations

Bhardwaj, Rajinder, Jennifer Madonia, Matt S. Anderson, et al.. (2024). Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects. Clinical and Translational Science. 17(10). e70015–e70015. 4 indexed citations

Bhardwaj, Rajinder, Jennifer Madonia, Matt S. Anderson, et al.. (2024). Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics. Clinical and Translational Science. 17(12). e70048–e70048. 1 indexed citations

Piscitelli, Joseph, Micaela B. Reddy, Lance Wollenberg, et al.. (2024). Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration. Clinical Pharmacokinetics. 63(4). 483–496. 4 indexed citations

Bhardwaj, Rajinder, Jennifer Madonia, Beth Morris, et al.. (2024). Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment. Clinical and Translational Science. 17(7). e13813–e13813. 4 indexed citations

Bhardwaj, Rajinder, et al.. (2024). No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults. Clinical and Translational Science. 17(3). e13727–e13727. 3 indexed citations

10.

Bertz, Richard, Julie L. Collins, Jennifer Madonia, et al.. (2024). Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study. Headache The Journal of Head and Face Pain. 65(3). 484–494. 2 indexed citations

11.

Bhardwaj, Rajinder, Beth Morris, Kyle Matschke, et al.. (2024). A Drug‐Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2‐ and MATE1‐Mediated Transport of Metformin in Healthy Participants. Clinical Pharmacology in Drug Development. 13(5). 465–473.

12.

Matschke, Kyle, Yali Liang, Hua Wei, et al.. (2019). Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. Clinical Pharmacology in Drug Development. 8(7). 884–894. 4 indexed citations

13.

Sahasrabudhe, Vaishali, Steven G. Terra, Anne Hickman, et al.. (2018). Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. Clinical Therapeutics. 40(10). 1701–1710. 19 indexed citations

14.

Sahasrabudhe, Vaishali, Yali Liang, Kyle Matschke, et al.. (2018). Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. Clinical Therapeutics. 40(9). 1538–1547. 19 indexed citations

15.

Malhotra, Bimal, et al.. (2015). Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02). Clinical Drug Investigation. 35(4). 267–274. 8 indexed citations

16.

Gandelman, Kuan, et al.. (2014). (413) Single- and multiple-dose study to evaluate pharmacokinetics, safety and tolerability of extended-release oxycodone with sequestered naltrexone (ALO-02) in healthy volunteers: a comparison of ALO-02 40 mg twice daily to OxyContin 40 mg twice daily and ALO-02 80 mg once daily. Journal of Pain. 15(4). S79–S79. 1 indexed citations

17.

Setnik, Beatrice, Almasa Bass, Candace Bramson, et al.. (2014). (412) Abuse potential study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to non-dependent, recreational opioid users. Journal of Pain. 15(4). S79–S79. 7 indexed citations

18.

Korth‐Bradley, Joan, Virginia Parks, Frank Wagner, et al.. (2013). Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. Clinical Pharmacology in Drug Development. 3(2). 151–157. 15 indexed citations

19.

Tortorici, Michael A., Virginia Parks, Kyle Matschke, Joan Korth‐Bradley, & Alain Patat. (2012). The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology. 69(4). 835–842. 7 indexed citations

20.

Korth‐Bradley, Joan, Steven Troy, Kyle Matschke, et al.. (2011). Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function. The Journal of Clinical Pharmacology. 52(9). 1379–1387. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact